Experimental Therapeutics Program

实验治疗计划

• 批准号: 10267041
• 负责人: MARIA R BAER
• 金额: $ 4.9万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-08 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10267041
• 关键词: Address; Advisory Committees; Baltimore; Basic Science; Biometry; Cancer Center; Catchment Area; Cigarette; Clinic; Clinical; Clinical Investigator; Collaborations; Community Outreach; Comprehensive Cancer Center; County; Detection; Development; Diagnosis; Diagnostic; Direct Costs; Doctor of Medicine; Doctor of Philosophy; Early Diagnosis; Faculty; Flow Cytometry; Funding; Funding Agency; Genomics; Goals; Grant; Hematologic Neoplasms; Human; Image; In Vitro; Industry; Institutes; Investigational Therapies; Journals; Laboratories; Laboratory Study; Leadership; Malignant Neoplasms; Maryland; Measurement; Medical; Medical center; Mission; Molecular; Molecular Biology; Molecular Target; NCI Center for Cancer Research; Nanotechnology; Pathology; Patient-Focused Outcomes; Peer Review; Pharmacy Schools; Population Sciences; Positioning Attribute; Preclinical Testing; Public Health Schools; Publications; Radiation Oncology; Radiation Protection; Radiation therapy; Research; Research Personnel; Research Priority; School Dentistry; Services; Solid Neoplasm; Source; Suggestion; System; Testing; Therapeutic; Translating; Treatment outcome; Universities; acronyms; anticancer research; base; biobank; cancer therapy; college; community engagement; early phase clinical trial; hormone related cancer; improved; in vivo; innovation; liquid biopsy; medical schools; member; molecular carrier; neoplasm immunotherapy; new technology; novel; novel therapeutic intervention; novel therapeutics; pre-clinical; pre-clinical research; professor; programs; recruit; research clinical testing; response; structural biology; translational scientist; tumor immunology; virology; Address; Advisory Committees; Baltimore; Basic Science; Biometry; Cancer Center; Catchment Area; Cigarette; Clinic; Clinical; Clinical Investigator; Collaborations; Community Outreach; Comprehensive Cancer Center; County; Detection; Development; Diagnosis; Diagnostic; Direct Costs; Doctor of Medicine; Doctor of Philosophy; Early Diagnosis; Faculty; Flow Cytometry; Funding; Funding Agency; Genomics; Goals; Grant; Hematologic Neoplasms; Human; Image; In Vitro; Industry; Institutes; Investigational Therapies; Journals; Laboratories; Laboratory Study; Leadership; Malignant Neoplasms; Maryland; Measurement; Medical; Medical center; Mission; Molecular; Molecular Biology; Molecular Target; NCI Center for Cancer Research; Nanotechnology; Pathology; Patient-Focused Outcomes; Peer Review; Pharmacy Schools; Population Sciences; Positioning Attribute; Preclinical Testing; Public Health Schools; Publications; Radiation Oncology; Radiation Protection; Radiation therapy; Research; Research Personnel; Research Priority; School Dentistry; Services; Solid Neoplasm; Source; Suggestion; System; Testing; Therapeutic; Translating; Treatment outcome; Universities; acronyms; anticancer research; base; biobank; cancer therapy; college; community engagement; early phase clinical trial; hormone related cancer; improved; in vivo; innovation; liquid biopsy; medical schools; member; molecular carrier; neoplasm immunotherapy; new technology; novel; novel therapeutic intervention; novel therapeutics; pre-clinical; pre-clinical research; professor; programs; recruit; research clinical testing; response; structural biology; translational scientist; tumor immunology; virology

10.0 Abstract: Experimental Therapeutics (ET) Program The overarching goal of ET is to develop and test new therapies for solid tumors and hematologic malignancies based on innovative preclinical research. The emphasis is on bringing basic and preclinical discoveries from ET members to early-stage clinical testing and also on providing platforms for investigators in other programs to evaluate their findings in clinical settings. To achieve this mission, the program focuses on three specific aims: Aim 1: Target detection and measurement—Investigate diagnostic advances, including molecular early detection, liquid biopsy and imaging, to guide new treatment approaches and assessments of response; Aim 2: Molecular targeting: Development and preclinical and clinical testing—Investigate new cancer therapies based on novel molecular targets in in vitro and in vivo laboratory studies as well as early phase clinical trials; and Aim 3: Treatment delivery: Novel delivery strategies—Investigate the development of new technologies for therapy delivery, including molecular carriers, nanotechnology, and novel radiation therapy and radiation protection approaches. To achieve these three aims, members of ET are supported by extensive expertise available in other University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC) Programs to translate basic research findings to the clinic and by the availability of exceptional shared services. The ET Program has 56 members, including 31 full members and 25 associate members, who conduct cancer-focused research that receives $14.6 million direct cost annual funding ($19.4 million total), including $3.6 million (25%) from NCI and $4.1 million from other peer-reviewed sources. ET Program members receive $6.9 million annually from non-peer-reviewed funding sources. During this funding period, ET members authored 889 cancer-related publications, of which 22% resulted from intraprogrammatic, 21% from interprogrammatic, and 8% from intra- and interprogrammatic collaborations. Of the 889 publications, 72% include collaborations with external investigators, reflecting the high national impact of the ET Program. A high percentage of ET publications (14%) were in journals with an impact factor ≥10. Research efforts of ET members are supported by extensive use of all shared services. The ET Program collaborates with the other four UMGCCC research programs and facilitate community outreach and engagement (COE) to identify and address the cancer research priorities of the catchment area.

10.0摘要：实验治疗（ET）程序 ET的总体目标是开发和测试实体瘤和血液学恶性肿的新疗法 基于创新的临床前研究。重点是从ET带来基本和临床前的发现 成员进行早期临床测试，并为其他计划中的调查人员提供平台 评估他们在临床环境中的发现。为了实现这一任务，该计划侧重于三个具体目标： 目标1：目标检测和测量 - 进一步进行诊断进步，包括早期分子 检测，液体活检和成像，以指导新的治疗方法和反应评估；目标2： 分子靶向：开发，临床前和临床测试 - 进行新的癌症治疗 基于体外和体内实验室研究的新型分子靶标以及早期临床试验； 和目标3：治疗交付：新颖的交付策略 - 进行新技术的发展 用于递送治疗，包括分子载体，纳米技术以及新型放射治疗和辐射 保护方法。为了实现这三个目标，ET的成员得到了广泛的专业知识的支持 在马里兰州其他大学和斯图尔特·格林巴姆综合癌症中心可用 （UMGCCC）将基础研究结果转化为诊所的程序并通过卓越的可用性 共享服务。 ET计划有56名成员，其中包括31名成员和25名员工，他们 进行以癌症为中心的研究，该研究获得了1460万美元的直接成本年度资金（总计1,940万美元）， 包括NCI的360万美元（25％）和其他同行评审来源的410万美元。 ET计划成员 每年从未经审查的资金来源获得690万美元。在此资助期间，ET成员 撰写了889个与癌症相关的出版物，其中22％是由术中产生的，21％来自 解释性含量为8％，分别是内部和解释合作的合作。在889个出版物中，有72％ 包括与外部研究人员的合作，反映了ET计划的重大影响。高 ET出版物的百分比（14％）是在影响因子≥10的期刊中。 ET成员的研究工作 广泛使用所有共享服务的支持。 ET计划与其他四个UMGCCC合作 研究计划并促进社区宣传与参与（COE）识别和解决癌症 集水区的研究重点。